Why the study?
Does catheter-based myocardial gene transfer of phVEGF-2 improve safety, symptoms, and myocardial perfusion in patients with chronic myocardial ischemia?
Population
n=6 patients with chronic myocardial ischemia
Comparison
Catheter-based myocardial gene transfer of naked… vs Placebo (mock procedure)
Design
RCT, 1:1, Single-blind, placebo-controlled
Follow-up
up to 360 days
Authors
Loading...
Supports gene therapy for refractory ischemia; extends preclinical VEGF data to clinical RCT evidence.
Does catheter-based myocardial gene transfer of phVEGF-2 improve safety, symptoms, and myocardial perfusion in patients with chronic myocardial ischemia?
Catheter-based myocardial gene transfer of phVEGF-2 is feasible and safe, with preliminary evidence of reduced ischemia and angina in patients with chronic myocardial ischemia.
Vale et al. (2001) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: